CTRI/2024/12/078773尚未招募2 期
Evaluation of efficacy of add on oral ribavirin in children with acute viral encephalitis aged 1-18 years: an open labelled randomized controlled trial
Dr Prateek Kumar Panda1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2025年1月15日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Survival without severe disability
研究概览
简要总结
This open-labeled randomized controlled trial will compare the efficacy of add-on oral ribavirin in children aged 1-18 years, with viral encephalitis. The intervention group will receive add-on oral ribavirin for seven days. The control group will receive only intravenous acyclovir for seven days. We will compare the survival rate without severe disability and the duration of hospitalization in both groups.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 1.00 Year(s) 至 18.00 Year(s)（—）
- 性别
- All
入选标准
- •Children with diagnosis of viral encephalitis.
排除标准
- •Children with chronic major systemic illness Previous documented allergy to ribavirin.
结局指标
主要结局
Survival without severe disability
时间窗: At 3 months after randomization
次要结局
- Cognition of each participant as measured by the Vineland Social Maturity Scale(At 3 months follow up after completing the seven day course of study medication)
研究者
Dr Prateek Kumar Panda
All India Institute of Medical Sciences, Rishikesh
研究点 (1)
Loading locations...
相似试验
尚未招募
1/2 期
DORAL2024-513941-35-00Centre de Recherches et d’Etudes sur les Pathologies Infectieuses, Tropicales et le VIH/Sida118
尚未招募
2 期
A Prospective Study to Evaluate the Efficacy and Safety of Entecavir ODT Conversion in Stable Liver Transplant PatientsNCT07267208Jongman Kim82
招募中
3 期
A Study to Evaluate Tobevibart+Elebsiran in Participants with Chronic HDV Infection Not Virologically Suppressed with Bulevirtide2024-519282-22-00Vir Biotechnology Inc.132
招募中
2 期
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 PatientsImmunodeficiencyNCT07406217Calmy Alexandra256
招募中
3 期
Pilot study, open label, multicenter, evaluating dual antiretroviral therapy with long-acting cabotegravir/lenacapavir IMEA 069 - CALENDULA2024-516028-33-01Inst Medecine Epidemiologie Appliquee30